Dr. Reddy’s shares drop up to 3% after semaglutide batch issue delays commercial supply
AI Market Summary
Dr. Reddy's disclosed certain semaglutide batches were out of specification due to an API issue, prompting a temporary commercial supply delay for its recently launched Canadian product (a projected $120m revenue opportunity). While the company stated patient safety and regulatory filings are unaffected, the update increases execution risk around a key growth driver and triggered a notable single-day share decline, reinforcing cautious broker positioning.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.14%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Dr. Reddy’s Laboratories said some semaglutide batches were found out of specification due to an issue linked to the active pharmaceutical ingredient, and that commercial supplies will be delayed for a period. The company added that the issue does not affect patient safety or the product’s existing global regulatory filings. The update pushed the stock down as much as 3%, and it was last trading 1.1% lower at ₹1,334.
